CAR-T cell therapy for multiple myeloma patients
Part of Cancer clinical trials.
This trial tests a new type of CAR-T cell treatment for multiple myeloma that uses donor cells. It's for patients whose cancer came back or didn't fully respond to prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma and it did not get better after at least 2 prior treatments.
- You cannot take standard stem cell transplant because of age or other health problems.
- Your last cancer treatment stopped working within 1 year.
- You are expected to live at least 12 more weeks.
- Your liver and kidney function are adequate.
- You are not pregnant, do not have an active infection, and have not had CAR-T therapy before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immunotherapy called Multi-CAR T cells for people with multiple myeloma that has come back or not responded to other treatments. It aims to see if these specially engineered cells can better fight the cancer.
This trial tests a new type of immunotherapy called CAR-T cells given as part of an early treatment plan for multiple myeloma or plasmacytoma. The goal is to see if this approach can help achieve a deep remission, especially after a stem cell transplant.
This trial tests a new type of cell therapy (CAR-T) that targets two proteins on myeloma cells: GPRC5D and CD19. It is for people whose myeloma has come back or stopped responding to at least 3 prior treatments. The goal is to see if this treatment is safe and helps control the disease.
This study tests a new type of cell therapy called CAR-T, which uses your own immune cells to fight the cancer. It is for people with multiple myeloma that has come back or not responded to at least three previous treatments.
This trial tests a CAR-T cell therapy for multiple myeloma that has come back or not responded to at least three prior treatments. It aims to see if this immunotherapy can help control the disease.
This trial tests combining CAR-T cell therapy with a donor stem cell transplant for multiple myeloma that has come back or not responded to treatment. It aims to see if this approach can help when other treatments have failed.
Hear when a new Multiple Myeloma in Remission trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.